|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/2/2012 10:18:59 AM
NEW YORK, Aug. 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that the United States Patent and Trademark Office issued Patent No. 8,232,262 entitled "Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents" with claims directed to pharmaceutical compositions, methods of treatment and methods of making a novel DNA cross-linker, including palifosfamide (ZIO-201). This newly issued patent provides subject matter exclusivity through 2027. The patent estate covering palifosfamide compositions, formulations, methods of use and methods of manufacture now includes issued patents in the United States, Australia, Europe, New Zealand and South Africa, as well as pending applications in the United States and various foreign jurisdictions.
|
|
|
|
|
|
|
|
|
|
|